Txcell
Valbonne, FR· latest recorded location
TXCELL is named on 7 US grants and 18 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 7
- Published applications
- 18
- Inventors
- 16
- Granted in 2026 so far
- 0
- Most recent grant
- 13 Dec 2016
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 1 | 3 |
| 2011 | 2 | 3 |
| 2012 | 0 | 0 |
| 2013 | 0 | 3 |
| 2014 | 2 | 1 |
| 2015 | 1 | 3 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 1 |
By publication year.
Technology areas
Share of 25 documents
Recent patents
- Compositions for treating multiple sclerosis13 Dec 2016US 9,517,253 B2
- Compositions for treating an intestinal inflammatory condition31 Mar 2015US 8,992,907 B2
- Method for assessing the efficacy of a TR1 cell therapy in a subject26 Aug 2014US 8,815,534 B2
- In vitro production of a cell population using feeder cells13 May 2014US 8,722,401 B2
- Tr1 cells for use in atherosclerosis26 Jul 2011US 7,985,409 B2
- Compositions for treating an arthritic condition6 Sep 2018US 2018/0250372 A1
- Compositions for treating multiple sclerosis16 Feb 2017US 2017/0042992 A1
- Compositions for treating an inflammatory autoimmune condition29 Oct 2015US 2015/0306143 A1
- Compositions for treating an intestinal inflammatory condition11 Jun 2015US 2015/0157707 A1
- Compositions for treating uveitis5 Mar 2015US 2015/0064206 A1
Most cited
By later US patents
- In vitro production of a cell population using feeder cells7US 8,722,401 B22014
- Method for identification of Tr1 lymphocytes regulators by the presence and over-expression of specific molecules and application thereof5US 7,771,932 B12010
- Obtention of food- or auto-antigen specific TR1 cells from a leukocyte or PBMC population1US 7,977,093 B22011